Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European ...
wvgazettemail.com

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved ...
Morningstar

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio ...
Seeking Alpha

Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis NEW YORK, Sept. 11, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. ...
PharmExec

Hoth Therapeutics Files Two Provisional Patent Applications to Expand Product Portfolio

Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the company’s intellectual property portfolio along with establishing a new ...
Yahoo Finance

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full ...